Ozempi c lowers blood glucose through mechanisms that stimulate insulin secretion and decrease glucagon secretion, both of which are glucose-dependent. Thus when blood glucose is elevated, insulin secretion is stimulated and glucagon secretion is inhibited.
The mechanism by which Ozempi c lowers blood sugar also involves a slight delay in early postprandial gastric emptying. The main mechanism of prolonging the half-life of Ozempi c is binding to albumin, reducing its renal clearance and protecting it from metabolic degradation. In addition, Ozempi c can resist the degradation of DPP-4 enzyme and remain stable.
Specifications: 1.34mg/ml, 1.5ml (pre-filled injection pen); 1.34mg/ml, 3ml (pre-filled injection pen).
1ml of injection contains 1.34mg of Ozempi c , which is a human glucagon-like peptide-1 (GLP-1) analogue produced by Saccharomyces cerevisiae cells through genetic recombination technology, and is a colorless or almost colorless clear isotonic liquid.
Usage: The drug is injected once a week, and can be injected at any time of the day. It does not need to be administered according to the meal time. It is administered by subcutaneous injection, and the injection site can be selected from the abdomen, thigh or upper arm. Dosage adjustment is not required when changing the injection site, and it cannot be injected intravenously or intramuscularly. The days of weekly dosing can be changed if necessary, as long as there is at least 2 days (>48 hours) between doses. Once a new dosing time is selected, weekly dosing should continue.
Before first use: store in refrigerator (2°C-8°C). Keep away from freezing elements. Do not freeze this product and do not use if frozen. Cover the pen cap to protect from light.
After first use: store in an environment below 30°C or in a refrigerator (2°C-8°C). Do not freeze this product and do not use if frozen. Cover the pen cap when not in use to keep it away from light.
The needle should be removed after each injection and when storing this product. This prevents needle blockage, contamination, infection, solution leakage and inaccurate dosing.
Dosage: The starting dose of Ozempi c is 0.25 mg once a week. After 4 weeks, it should be increased to 0.5mg once a week. After at least 4 weeks of treatment with 0.5 mg once weekly, the dose may be increased to 1 mg once weekly to further improve glycemic control. This product 0.25mg is not a maintenance dose. Doses exceeding 1 mg per week are not recommended.
When Ozempi c is used in combination with existing metformin therapy, the current dose of metformin can be maintained unchanged. When this product is used in combination with existing sulfonylureas, the dose of sulfonylureas should be considered to reduce the risk of hypoglycemia. Self-monitoring of blood glucose is not required to adjust the dose of this product. However, when starting to use this product in combination with sulfonylureas, self-monitoring of blood glucose may be required to adjust the dose of sulfonylureas to reduce the risk of hypoglycemia.
Audited Supplier 
){kind=link}